86 Morris Avenue
BUILDING FOR SUCCESS
Celgene Corporation is delivering the promise of science to patients and their families facing extraordinary challenges with cancer and inflammatory disease through innovative next generation therapies. Driving profitability are marketed products, which include THALOMID (thalidomide), ALKERAN (melphalan), Focalin™, cellular and tissue therapeutics, as well as the Ritalin family of drugs.
Celgene, as a leader in global biotechnology, has built a meaningfully integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and cell-based therapies and spans the critical functions required to generate a large and diverse pipeline of innovative next generation drugs and cell therapies that address the source of the disease and not just the symptoms.
RECENT PIPELINE HIGHLIGHTS
REVIMID: In February 2003 and April 2003, REVIMID received fast track designation from the FDA for the treatment of multiple myeloma and myelodysplastic syndromes, respectively. REVIMID is currently being tested in two pivotal Phase III FDA SPA trials for the treatment of multiple myeloma and metastatic melanoma. Furthermore, in May, at the International Myelodysplastic Syndromes meeting in Paris, France, REVIMID was the highlight of a study demonstrating medically meaningful erythroid and cytogenic response in MDS patients. That study, initiated by Dr. Alan List of the Moffitt Cancer Center, Tampa Florida, provided the foundation for Celgene to accelerate the potential approval of REVIMID by initiating four Phase II clinical trials; two multicenter Phase II studies in red blood cell transfusion dependent subjects with MDS with or without an associated 5Q minus cytogenetic abnormality and one phase II study in multiple myeloma.
THALOMID: Clinical investigators from leading cancer research centers around the world presented clinical data on THALOMID (thalidomide) in a broad range of hematological malignancies and solid tumor cancers at the Ninth Multiple Myeloma Workshop in Salamanca, Spain and at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, respectively. Several highlighted presentations provided new information on the potential of THALOMID across all stages of multiple myeloma as well as a wide range of solid tumor cancers, including renal cell carcinoma, prostate cancer and malignant melanoma.
ACTIMID™: Our next high-potential orally administered IMiD, is being evaluated in a Phase I/II clinical trial in refractory multiple myeloma and Phase II clinical trial in Prostate cancer. Interim data from an ongoing Phase I/II trial of ACTIMID in 18 relapsed and refractory multiple myeloma patients indicates that ACTIMID has anti-tumor activity in multiple myeloma and has an acceptable toxicity profile.
John W. Jackson - Executive Chairman
Sol J. Barer - Chief Executive Officer
Robert J. Hugin - President and Chief Operating Officer
771 articles with Celgene
RELIEF™ trial demonstrated statistically significant reductions in oral ulcers with apremilast 30 mg versus placebo through week 12.
OTEZLA (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
The results showed that a higher proportion of patients taking apremilast 30 mg twice daily (BID) achieved clinical remission versus placebo (nominally significant, P<0.05).
Weiland has over 30 years in the healthcare industry and was most recently the President and Chief Operating Officer of C.R. Bard (Bard).
This open-ended program is effective immediately.
Bob Hugin announced his campaign on Monday in an email.
Of these notes, $500 million will mature in 2021 and will bear interest at an annual rate of 2.875 percent, $1.0 billion will mature in 2023 and will bear interest at an annual rate of 3.25 percent, $1.5 billion will mature in 2028 and will bear interest at an annual rate of 3.90 percent and $1.5 billion will mature in 2048 and will bear interest at an annual rate of 4.55 percent.
Celgene Announces Offering of Senior Unsecured Notes Under a Shelf Registration Statement on Form S-3
The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
The international clinical study, OPTIMISMM, achieved its primary endpoint.
Juno's Hans Bishop will take home $287M after Celgene acquired his company.
The tender offer is being made in connection with the Agreement and Plan of Merger, dated January 21, 2018, by and among Celgene, Blue Magpie Corporation and Juno.
Sometimes the biggest are also the best. That's the case for biotherapeutics stocks.
A look at three big biotech companies that have big catalysts this year that could have a, you guessed it, big effect.
Celgene Announces Retirement of Executive Chairman Bob Hugin and Appointment of CEO Mark Alles as Chairman of the Board of Directors
Celgene Corporation today announced that Executive Chairman Bob Hugin has decided to retire from Celgene after 19 years of service and to step down from the Celgene Board of Directors, effective February 5, 2018.
The company made some bold moves this month in acquiring Juno and Impact
For the fourth quarter of 2017, net product sales were $3,479 million, an increase of 17 percent, year-over-year.
Employees of Juno received a surprise in their Monday morning emails.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
Investigational Data Presented at ASCO GI Evaluate ABRAXANE Regimen for Patients with Locally Advanced Pancreatic Cancer
An analysis of patients with newly diagnosed, locally advanced pancreatic cancer treated with up to 6 cycles of ABRAXANE + gemcitabine as an investigational induction therapy (n=106) found that patients had a median time to treatment failure (TTF) of 8.8 months (90% CI: 6.67-9.82), which exceeded the protocol-specified target of 6.6 months (primary endpoint).
Investors and analysts have given it some thought and mostly think it's a sensible acquisition.
Fresh off its $7B acquisition, Celgene is planning to open a biopharma incubator on its corporate campus in New Jersey.